FY2029 Earnings Estimate for ZVRA Issued By Roth Capital

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for shares of Zevra Therapeutics in a note issued to investors on Sunday, February 9th. Roth Capital analyst J. Aschoff expects that the company will post earnings of $2.26 per share for the year. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

A number of other analysts have also recently weighed in on ZVRA. Cantor Fitzgerald raised Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $21.57.

Zevra Therapeutics Stock Down 3.1 %

NASDAQ:ZVRA opened at $7.53 on Tuesday. The company’s 50-day simple moving average is $8.37 and its 200-day simple moving average is $8.01. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter last year, the firm earned ($0.40) EPS.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ZVRA. FMR LLC increased its holdings in Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after buying an additional 2,312,384 shares during the period. Geode Capital Management LLC increased its stake in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after acquiring an additional 129,600 shares during the period. State Street Corp raised its holdings in shares of Zevra Therapeutics by 7.4% during the third quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after purchasing an additional 52,966 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in Zevra Therapeutics during the third quarter valued at $4,858,000. Finally, Vestal Point Capital LP purchased a new stake in Zevra Therapeutics in the third quarter valued at $3,644,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.